The dual inhibitor of the phosphoinositol-3 and PIM kinases, IBL-202, is effective against chronic lymphocytic leukaemia cells under conditions that mimic the hypoxic tumour microenvironment.

The dual inhibitor of the phosphoinositol-3 and PIM kinases, IBL-202, is effective against chronic lymphocytic leukaemia cells under conditions that mimic the hypoxic tumour microenvironment. Br J Haematol. 2018 09; 182(5):654-669.

View in: PubMed

subject areas

Cell Movement
Cell Proliferation
Drug Synergism
Humans
Integrin alpha4
Leukemia, Lymphocytic, Chronic, B-Cell
Protein Kinase Inhibitors
Proto-Oncogene Proteins c-pim-1
Purines
Quinazolinones
Receptors, Antigen, B-Cell
Receptors, CXCR4
Tumor Cells, Cultured
Tumor Microenvironment

authors with profiles

Michael Joseph O'Dwyer